PERTH, AUSTRALIA: February 05, 2013 – Phylogica Ltd (ASX:PYC, XETRA: PH7), a leading Australian peptide drug discovery company, announced today that it has entered an agreement with Bio-Link Australia Pty. Ltd., a specialist life sciences business development company, to commercialise a family of anti-inflammatory Phylomer peptides for pharmaceutical use. Under the terms of the agreement, Bio-Link will work with Phylogica to monetize these assets through out-licensing or disposal of the Phylomer peptides to a pharmaceutical or biotechnology company.
The family of anti-inflammatory Phylomer peptides, including lead candidates PYC35, PYC36, PYC38 and PYC98, target the AP-1 pathway, which is a crucial mediator of inflammation in various diseases. The AP-1 pathway plays a critical role in neuronal cell death caused by stroke and traumatic brain injury, and lung inflammation resulting from acute respiratory distress syndrome (ARDS) and septic shock. The family of Phylomer peptides have demonstrated efficacy in multiple preclinical models for stroke, traumatic brain injury and ARDS.
For further information please download PDF below:
